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In a controlled industry, such as the pharmaceutical business where marketing
communication is restricted by Act of Parliament, product or service differentiation
strategies which include advertising are difficult to implement. Section 98 of the
2003 Tanzania Food, Drugs and Cosmetics Act imposes tough restrictions on
advertising or promoting products regulated by the Act. Thus formulating and
executing competitive marketing strategies are extremely challenging since
competition in this industry is supposed to be a win-win situation, creating value for
customers, instead of gravitating to zero-sum competition in which the gains of one
system participant come at the expense of others. In red oceans where players
compete head-on, competition drives profits to shrink.
This calls for creation and capture of new uncontested market space - blue oceans -
which make competition irrelevant and lead to business growth and profitability. The
aim of this study was to describe the creation and capture of new uncontested market
space by companies engaged in pharmaceutical business in Tanzania. Specifically
the study intended to describe how pharmaceutical companies create and capture
uncontested market space and establish extent to which the prevailing regulatory
environment affects strategies developed by pharmaceutical companies. Primary data
were collected from 79 pharmaceutical companies in five cities of Tanzania by use
of a structured interviewer-administered open-ended questionnaire. Ninety percent of
planned interviews were completed. Officials of TFDA and the Pharmacy Council
were also interviewed on the prevailing regulatory environment and how it affects
strategies developed by pharmaceutical companies. Quantitative data were analyzed
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using Microsoft Excel while qualitative data were coded and grouped in themes and
summarized using Microsoft Word.
All companies described employing competition-driven strategies. Strategic
categories in the pharmaceutical business include manufacturing, wholesaling,
importation, and retailing. Key competition factors include product price lowering,
raw material or product sourcing from competitive sources, employee skills and
experience, ensuring that stocks include a wide range of products and that there are
no stock outs, quality of customer service, and products' country of origin which is
linked to product quality.
10% (8) of the respondents were able to describe strategic moves by their companies
which have delivered products and services that opened up and captured new market
space - blue oceans - with significant leap in demand that led to profitable growth.
Strategy formulation did not use specific tools, but all described how they
entertained a profitable business idea through meetings and in-house brainstorming
to implementation.
The pharmaceutical business in Tanzania is largely controlled and regulated by
TFDA (pharmaceutical products) and the Pharmacy Council (professional conduct
and practice).
Since marketing in the pharmaceutical business is restricted by law, business
managers need training on how to effectively formulate and execute business
lX
strategies that create a leap in demand and lead to profitable growth without
compromising on the part of the customer.
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